Our Work
Latham Advises on Orchestra BioMed’s Completed Business Combination With Health Sciences Acquisitions Corporation 2
January 27, 2023
Firm represents the capital markets and financial advisors in the deSPAC transaction.
Orchestra BioMed, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, has announced the closing of its previously announced business combination with Health Sciences Acquisitions Corporation 2 (HSAC2) (Nasdaq: HSAQ). Common stock of the combined company (Nasdaq: OBIO or the Company), which is called “Orchestra BioMed Holdings, Inc.”, will commence trading on January 27, 2023, on the Nasdaq Global Market under the ticker symbol “OBIO”.
Latham & Watkins LLP represented the capital markets and financial advisors in the deSPAC transaction with a New York corporate team led by partner Nathan Ajiashvili, with associates Katie Lovejoy and Angel Marcial.